Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Experimental Hematology & Oncology
Published in: Experimental Hematology & Oncology 1/2013

Open Access 01-12-2013 | Review

Three are better than one: plasminogen receptors as cancer theranostic targets

Authors: Patrizia Ceruti, Moitza Principe, Michela Capello, Paola Cappello, Francesco Novelli

Published in: Experimental Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

Activation of plasminogen on the cell surface initiates a cascade of protease activity with important implications for several physiological and pathological events. In particular, components of the plasminogen system participate in tumor growth, invasion and metastasis. Plasminogen receptors are in fact expressed on the cell surface of most tumors, and their expression frequently correlates with cancer diagnosis, survival and prognosis. Notably, they can trigger multiple specific immune responses in cancer patients, highlighting their role as tumor-associated antigens. In this review, three of the most characterized plasminogen receptors involved in tumorigenesis, namely Annexin 2 (ANX2), Cytokeratin 8 (CK8) and alpha-Enolase (ENOA), are analyzed to ascertain an overall view of their role in the most common cancers. This analysis emphasizes the possibility of delineating new personalized therapeutic strategies to counteract tumor growth and metastasis by targeting plasminogen receptors, as well as their potential application as cancer predictors.
Literature
1.
Kwaan HC, McMahon B: The role of plasminogen-plasmin system in cancer. Cancer Treat Res 2009, 148: 43–66. 10.1007/978-0-387-79962-9_4PubMedCrossRef
2.
Andreasen PA, Egelund R, Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000, 57: 25–40. 10.1007/s000180050497PubMedCrossRef
3.
Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M, Romer J: Plasminogen activation and cancer. Thromb Haemost 2005, 93: 676–681.PubMed
4.
Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL: The cell biology of the plasminogen system. FASEB J 1995, 9: 939–945.PubMed
5.
McMahon B, Kwaan HC: The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 2008, 36: 184–194.PubMedCrossRef
6.
Shin SJ, Kim KO, Kim MK, Lee KH, Hyun MS, Kim KJ, Choi JH, Song HS: Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer. Jpn J Clin Oncol 2005, 35: 342–348. 10.1093/jjco/hyi094PubMedCrossRef
7.
Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC: Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 2008, 36: 160–167. 10.1097/MPA.0b013e31815750f0PubMedCrossRef
8.
Tang L, Han X: The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed Pharmacother 2013, 67: 179–182. 10.1016/j.biopha.2012.10.003PubMedCrossRef
9.
Zhang W, Ling D, Tan J, Zhang J, Li L: Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance. Oncol Rep 2013, 29: 637–645.PubMed
10.
Markl B, Renk I, Oruzio DV, Jahnig H, Schenkirsch G, Scholer C, Ehret W, Arnholdt HM, Anthuber M, Spatz H: Tumour budding, uPA and PAI-1 are associated with aggressive behaviour in colon cancer. J Surg Oncol 2010, 102: 235–241. 10.1002/jso.21611PubMedCrossRef
11.
Berger DH: Plasmin/plasminogen system in colorectal cancer. World J Surg 2002, 26: 767–771. 10.1007/s00268-002-4050-8PubMedCrossRef
12.
13.
Petersen TE, Martzen MR, Ichinose A, Davie EW: Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem 1990, 265: 6104–6111.PubMed
14.
Hayes ML, Castellino FJ: Carbohydrate of the human plasminogen variants. I. Carbohydrate composition, glycopeptide isolation, and characterization. J Biol Chem 1979, 254: 8768–8771.PubMed
15.
Hayes ML, Castellino FJ: Carbohydrate of the human plasminogen variants. III. Structure of the O-glycosidically linked oligosaccharide unit. J Biol Chem 1979, 254: 8777–8780.PubMed
16.
17.
Castellino FJ, Ploplis VA: Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005, 93: 647–654.PubMed
18.
Paciucci R, Tora M, Diaz VM, Real FX: The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro. Oncogene 1998, 16: 625–633. 10.1038/sj.onc.1201564PubMedCrossRef
19.
Lijnen HR, Van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D: Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998, 18: 1035–1045. 10.1161/01.ATV.18.7.1035PubMedCrossRef
20.
Plow EF, Felez J, Miles LA: Cellular regulation of fibrinolysis. Thromb Haemost 1991, 66: 32–36.PubMed
21.
Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370: 61–65. 10.1038/370061a0PubMedCrossRef
22.
Vassalli JD, Pepper MS: Tumour biology. Membrane proteases in focus. Nature 1994, 370: 14–15. 10.1038/370014a0PubMedCrossRef
23.
Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF: Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 1991, 30: 1682–1691. 10.1021/bi00220a034PubMedCrossRef
24.
Miles LA, Hawley SB, Baik N, Andronicos NM, Castellino FJ, Parmer RJ: Plasminogen receptors: the sine qua non of cell surface plasminogen activation. Front Biosci 2005, 10: 1754–1762.PubMed
25.
Plow EF, Freaney DE, Plescia J, Miles LA: The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986, 103: 2411–2420. 10.1083/jcb.103.6.2411PubMedCrossRef
26.
Lopez-Alemany R, Longstaff C, Hawley S, Mirshahi M, Fabregas P, Jardi M, Merton E, Miles LA, Felez J: Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase. Am J Hematol 2003, 72: 234–242. 10.1002/ajh.10299PubMedCrossRef
27.
Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985, 44: 139–266.PubMedCrossRef
28.
Felez J: Plasminogen binding to cell surface. Fibrinolysis Proteolysis 1998, 12: 183–189. 10.1016/S0268-9499(98)80012-XCrossRef
29.
Liu KJ, Shih NY: The role of Enolase in tissue invasion and metastasis of pathogens and tumor cells. J Cancer Mol 2007, 3: 45–48.
30.
Borza DB, Morgan WT: Acceleration of plasminogen activation by tissue plasminogen activator on surface-bound histidine-proline-rich glycoprotein. J Biol Chem 1997, 272: 5718–5726. 10.1074/jbc.272.9.5718PubMedCrossRef
31.
Das R, Burke T, Plow EF: Histone H2B as a functionally important plasminogen receptor on macrophages. Blood 2007, 110: 3763–3772. 10.1182/blood-2007-03-079392PubMedCentralPubMedCrossRef
32.
Dudani AK, Cummings C, Hashemi S, Ganz PR: Isolation of a novel 45 kDa plasminogen receptor from human endothelial cells. Thromb Res 1993, 69: 185–196. 10.1016/0049-3848(93)90044-OPubMedCrossRef
33.
Dudani AK, Ganz PR: Endothelial cell surface actin serves as a binding site for plasminogen, tissue plasminogen activator and lipoprotein(a). Br J Haematol 1996, 95: 168–178. 10.1046/j.1365-2141.1996.7482367.xPubMedCrossRef
34.
Gonzalez-Gronow M, Kaczowka S, Gawdi G, Pizzo SV: Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor. Front Biosci 2008, 13: 1610–1618. 10.2741/2785PubMedCrossRef
35.
Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH: The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci 2008, 13: 1634–1645. 10.2741/2787PubMedCrossRef
36.
Herren T, Burke TA, Das R, Plow EF: Identification of histone H2B as a regulated plasminogen receptor. Biochemistry 2006, 45: 9463–9474. 10.1021/bi060756wPubMedCrossRef
37.
Kanalas JJ, Makker SP: Identification of the rat Heymann nephritis autoantigen (GP330) as a receptor site for plasminogen. J Biol Chem 1991, 266: 10825–10829.PubMed
38.
Lighvani S, Baik N, Diggs JE, Khaldoyanidi S, Parmer RJ, Miles LA: Regulation of macrophage migration by a novel plasminogen receptor Plg-R KT. Blood 2011, 118: 5622–5630. 10.1182/blood-2011-03-344242PubMedCentralPubMedCrossRef
39.
Phipps KD, Surette AP, O'Connell PA, Waisman DM: Plasminogen receptor S100A10 is essential for the migration of tumor-promoting macrophages into tumor sites. Cancer Res 2011, 71: 6676–6683. 10.1158/0008-5472.CAN-11-1748PubMedCrossRef
40.
Redlitz A, Fowler BJ, Plow EF, Miles LA: The role of an enolase-related molecule in plasminogen binding to cells. Eur J Biochem 1995, 227: 407–415. 10.1111/j.1432-1033.1995.tb20403.xPubMedCrossRef
41.
42.
Winram SB, Lottenberg R: The plasmin-binding protein Plr of group A streptococci is identified as glyceraldehyde-3-phosphate dehydrogenase. Microbiology 1996,142(Pt 8):2311–2320.PubMedCrossRef
43.
Andronicos NM, Chen EI, Baik N, Bai H, Parmer CM, Kiosses WB, Kamps MP, Yates JR 3rd, Parmer RJ, Miles LA: Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation. Blood 2010, 115: 1319–1330. 10.1182/blood-2008-11-188938PubMedCentralPubMedCrossRef
44.
Kang HJ, Jung SK, Kim SJ, Chung SJ: Structure of human alpha-enolase (hENO1), a multifunctional glycolytic enzyme. Acta Crystallogr D Biol Crystallogr 2008, 64: 651–657.PubMedCrossRef
45.
Kang HM, Choi KS, Kassam G, Fitzpatrick SL, Kwon M, Waisman DM: Role of annexin II tetramer in plasminogen activation. Trends Cardiovasc Med 1999, 9: 92–102. 10.1016/S1050-1738(99)00012-2PubMedCrossRef
46.
Liemann S, Lewit-Bentley A: Annexins: a novel family of calcium- and membrane-binding proteins in search of a function. Structure 1995, 3: 233–237. 10.1016/S0969-2126(01)00152-6PubMedCrossRef
47.
Shiozawa Y, Havens AM, Jung Y, Ziegler AM, Pedersen EA, Wang J, Lu G, Roodman GD, Loberg RD, Pienta KJ, Taichman RS: Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem 2008, 105: 370–380. 10.1002/jcb.21835PubMedCentralPubMedCrossRef
48.
Waisman DM: Annexin II tetramer: structure and function. Mol Cell Biochem 1995, 149–150: 301–322.PubMedCrossRef
49.
50.
51.
Gires O, Andratschke M, Schmitt B, Mack B, Schaffrik M: Cytokeratin 8 associates with the external leaflet of plasma membranes in tumour cells. Biochem Biophys Res Commun 2005, 328: 1154–1162. 10.1016/j.bbrc.2005.01.074PubMedCrossRef
52.
Hembrough TA, Li L, Gonias SL: Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J Biol Chem 1996, 271: 25684–25691. 10.1074/jbc.271.41.25684PubMedCrossRef
53.
Kralovich KR, Li L, Hembrough TA, Webb DJ, Karns LR, Gonias SL: Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18. J Protein Chem 1998, 17: 845–854. 10.1023/A:1020738620817PubMedCrossRef
54.
Pancholi V: Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 2001, 58: 902–920. 10.1007/PL00000910PubMedCrossRef
55.
Lohman K, Meyerhof O: Über die enzymatische Umwandlung von Phosphoglyzerinsäure in Brenztraubensäure und Phosphorsäure (Enzymatic transformation of phosphoglyceric acid into pyruvic and phosphoric acid). Biochem Z 1934, 273: 60–72.
56.
Giallongo A, Oliva D, Cali L, Barba G, Barbieri G, Feo S: Structure of the human gene for alpha-enolase. Eur J Biochem 1990, 190: 567–573. 10.1111/j.1432-1033.1990.tb15611.xPubMedCrossRef
57.
Marangos PJ, Zis AP, Clark RL, Goodwin FK: Neuronal, non-neuronal and hybrid forms of enolase in brain: structural, immunological and functional comparisons. Brain Res 1978, 150: 117–133. 10.1016/0006-8993(78)90657-1PubMedCrossRef
58.
Kato K, Asai R, Shimizu A, Suzuki F, Ariyoshi Y: Immunoassay of three enolase isozymes in human serum and in blood cells. Clin Chim Acta 1983, 127: 353–363. 10.1016/0009-8981(83)90162-6PubMedCrossRef
59.
Royds JA, Parsons MA, Taylor CB, Timperley WR: Enolase isoenzyme distribution in the human brain and its tumours. J Pathol 1982, 137: 37–49. 10.1002/path.1711370105PubMedCrossRef
60.
Asch HL, Mayhew E, Lazo RO, Asch BB: Lipids noncovalently associated with keratins and other cytoskeletal proteins of mouse mammary epithelial cells in primary culture. Biochim Biophys Acta 1990, 1034: 303–308. 10.1016/0304-4165(90)90056-3PubMedCrossRef
61.
Vidrich A, Gilmartin ME, Mitchell J, Freedberg IM: Postsynthetic modifications of epithelial keratins. Ann N Y Acad Sci 1985, 455: 354–370. 10.1111/j.1749-6632.1985.tb50422.xPubMedCrossRef
62.
Chan R, Rossitto PV, Edwards BF, Cardiff RD: Presence of proteolytically processed keratins in the culture medium of MCF-7 cells. Cancer Res 1986, 46: 6353–6359.PubMed
63.
Chou CF, Riopel CL, Rott LS, Omary MB: A significant soluble keratin fraction in 'simple' epithelial cells. Lack of an apparent phosphorylation and glycosylation role in keratin solubility. J Cell Sci 1993,105(Pt 2):433–444.PubMed
64.
Hembrough TA, Kralovich KR, Li L, Gonias SL: Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. Biochem J 1996,317(Pt 3):763–769.PubMedCentralPubMedCrossRef
65.
Zheng L, Foley K, Huang L, Leubner A, Mo G, Olino K, Edil BH, Mizuma M, Sharma R, Le DT: Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PLoS One 2011, 6: e19390. 10.1371/journal.pone.0019390PubMedCentralPubMedCrossRef
66.
Cooper JA, Esch FS, Taylor SS, Hunter T: Phosphorylation sites in enolase and lactate dehydrogenase utilized by tyrosine protein kinases in vivo and in vitro. J Biol Chem 1984, 259: 7835–7841.PubMed
67.
Capello M, Ferri-Borgogno S, Cappello P, Novelli F: alpha-Enolase: a promising therapeutic and diagnostic tumor target. FEBS J 2011, 278: 1064–1074. 10.1111/j.1742-4658.2011.08025.xPubMedCrossRef
68.
Bao H, Jiang M, Zhu M, Sheng F, Ruan J, Ruan C: Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol 2009, 90: 177–185. 10.1007/s12185-009-0356-8PubMedCrossRef
69.
Chiang Y, Rizzino A, Sibenaller ZA, Wold MS, Vishwanatha JK: Specific down-regulation of annexin II expression in human cells interferes with cell proliferation. Mol Cell Biochem 1999, 199: 139–147. 10.1023/A:1006942128672PubMedCrossRef
70.
71.
Hajjar KA, Krishnan S: Annexin II: a mediator of the plasmin/plasminogen activator system. Trends Cardiovasc Med 1999, 9: 128–138. 10.1016/S1050-1738(99)00020-1PubMedCrossRef
72.
Hajjar KA, Menell JS: Annexin II: a novel mediator of cell surface plasmin generation. Ann N Y Acad Sci 1997, 811: 337–349. 10.1111/j.1749-6632.1997.tb52013.xPubMedCrossRef
73.
Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, Hempstead B, Mark WH, Hajjar KA: Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 2004, 113: 38–48.PubMedCentralPubMedCrossRef
74.
Gould KL, Woodgett JR, Isacke CM, Hunter T: The protein-tyrosine kinase substrate p36 is also a substrate for protein kinase C in vitro and in vivo. Mol Cell Biol 1986, 6: 2738–2744.PubMedCentralPubMedCrossRef
75.
Hayes MJ, Moss SE: Annexin 2 has a dual role as regulator and effector of v-Src in cell transformation. J Biol Chem 2009, 284: 10202–10210. 10.1074/jbc.M807043200PubMedCentralPubMedCrossRef
76.
Hubaishy I, Jones PG, Bjorge J, Bellagamba C, Fitzpatrick S, Fujita DJ, Waisman DM: Modulation of annexin II tetramer by tyrosine phosphorylation. Biochem 1995, 34: 14527–14534. 10.1021/bi00044a031CrossRef
77.
Biener Y, Feinstein R, Mayak M, Kaburagi Y, Kadowaki T, Zick Y: Annexin II is a novel player in insulin signal transduction. Possible association between annexin II phosphorylation and insulin receptor internalization. J Biol Chem 1996, 271: 29489–29496. 10.1074/jbc.271.46.29489PubMedCrossRef
78.
Jiang Y, Chan JL, Zong CS, Wang LH: Effect of tyrosine mutations on the kinase activity and transforming potential of an oncogenic human insulin-like growth factor I receptor. J Biol Chem 1996, 271: 160–167. 10.1074/jbc.271.1.160PubMedCrossRef
79.
Brambilla R, Zippel R, Sturani E, Morello L, Peres A, Alberghina L: Characterization of the tyrosine phosphorylation of calpactin I (annexin II) induced by platelet-derived growth factor. Biochem J 1991,278(Pt 2):447–452.PubMedCentralPubMedCrossRef
80.
Zhao WQ, Chen GH, Chen H, Pascale A, Ravindranath L, Quon MJ, Alkon DL: Secretion of Annexin II via activation of insulin receptor and insulin-like growth factor receptor. J Biol Chem 2003, 278: 4205–4215. 10.1074/jbc.M210545200PubMedCrossRef
81.
Chen R, Brentnall TA, Pan S, Cooke K, Moyes KW, Lane Z, Crispin DA, Goodlett DR, Aebersold R, Bronner MP: Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cell Proteomics 2007, 6: 1331–1342. 10.1074/mcp.M700072-MCP200PubMedCrossRef
82.
Cole SP, Pinkoski MJ, Bhardwaj G, Deeley RG: Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br J Cancer 1992, 65: 498–502. 10.1038/bjc.1992.103PubMedCentralPubMedCrossRef
83.
Delys L, Detours V, Franc B, Thomas G, Bogdanova T, Tronko M, Libert F, Dumont JE, Maenhaut C: Gene expression and the biological phenotype of papillary thyroid carcinomas. Oncogene 2007, 26: 7894–7903. 10.1038/sj.onc.1210588PubMedCrossRef
84.
Domoto T, Miyama Y, Suzuki H, Teratani T, Arai K, Sugiyama T, Takayama T, Mugiya S, Ozono S, Nozawa R: Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci 2007, 98: 77–82. 10.1111/j.1349-7006.2006.00355.xPubMedCrossRef
85.
Emoto K, Sawada H, Yamada Y, Fujimoto H, Takahama Y, Ueno M, Takayama T, Uchida H, Kamada K, Naito A: Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 2001, 21: 1339–1345.PubMed
86.
Emoto K, Yamada Y, Sawada H, Fujimoto H, Ueno M, Takayama T, Kamada K, Naito A, Hirao S, Nakajima Y: Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 2001, 92: 1419–1426. 10.1002/1097-0142(20010915)92:6<1419::AID-CNCR1465>3.0.CO;2-JPubMedCrossRef
87.
Esposito I, Penzel R, Chaib-Harrireche M, Barcena U, Bergmann F, Riedl S, Kayed H, Giese N, Kleeff J, Friess H, Schirmacher P: Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol 2006, 208: 673–685. 10.1002/path.1935PubMedCrossRef
88.
Guedj N, Zhan Q, Perigny M, Rautou PE, Degos F, Belghiti J, Farges O, Bedossa P, Paradis V: Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. J Hepatol 2009, 51: 93–101. 10.1016/j.jhep.2009.03.017PubMedCrossRef
89.
Guzman Aranguez A, Olmo N, Turnay J, Lecona E, Perez Ramos P, Lopez De Silanes I, Lizarbe MA: Differentiation of human colon adenocarcinoma cells alters the expression and intracellular localization of annexins A1, A2, and A5. J Cell Biochem 2005, 94: 178–193. 10.1002/jcb.20293PubMedCrossRef
90.
Ji NY, Park MY, Kang YH, Lee CI, Kim DG, Yeom YI, Jang YJ, Myung PK, Kim JW, Lee HG: Evaluation of annexin II as a potential serum marker for hepatocellular carcinoma using a developed sandwich ELISA method. Int J Mol Med 2009, 24: 765–771.PubMed
91.
Liu Y, Wang Z, Jiang M, Dai L, Zhang W, Wu D, Ruan C: The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res 2011, 35: 879–884. 10.1016/j.leukres.2010.11.008PubMedCrossRef
92.
Liu Y, Zhu X, Zhu J, Liao S, Tang Q, Liu K, Guan X, Zhang J, Feng Z: Identification of differential expression of genes in hepatocellular carcinoma by suppression subtractive hybridization combined cDNA microarray. Oncol Rep 2007, 18: 943–951.PubMed
93.
Mohammad HS, Kurokohchi K, Yoneyama H, Tokuda M, Morishita A, Jian G, Shi L, Murota M, Tani J, Kato K: Annexin A2 expression and phosphorylation are up-regulated in hepatocellular carcinoma. Int J Oncol 2008, 33: 1157–1163.PubMed
94.
Musholt TJ, Hanack J, Brehm C, von Wasielewski R, Musholt PB: Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display. World J Surg 2005, 29: 472–482. 10.1007/s00268-004-7748-yPubMedCrossRef
95.
Olwill SA, McGlynn H, Gilmore WS, Alexander HD: Annexin II cell surface and mRNA expression in human acute myeloid leukaemia cell lines. Thromb Res 2005, 115: 109–114.PubMedCrossRef
96.
Pei H, Zhu H, Zeng S, Li Y, Yang H, Shen L, Chen J, Zeng L, Fan J, Li X: Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J Proteome Res 2007, 6: 2495–2501. 10.1021/pr060644rPubMedCrossRef
97.
Reeves SA, Chavez-Kappel C, Davis R, Rosenblum M, Israel MA: Developmental regulation of annexin II (Lipocortin 2) in human brain and expression in high grade glioma. Cancer Res 1992, 52: 6871–6876.PubMed
98.
Roseman BJ, Bollen A, Hsu J, Lamborn K, Israel MA: Annexin II marks astrocytic brain tumors of high histologic grade. Oncol Res 1994, 6: 561–567.PubMed
99.
Zhang J, Guo B, Zhang Y, Cao J, Chen T: Silencing of the annexin II gene down-regulates the levels of S100A10, c-Myc, and plasmin and inhibits breast cancer cell proliferation and invasion. Saudi Med J 2010, 31: 374–381.PubMed
100.
Zhong LP, Wei KJ, Yang X, Zhang L, Zhou XJ, Pan HY, Li J, Chen WT, Zhang ZY: Increased expression of Annexin A2 in oral squamous cell carcinoma. Arch Oral Biol 2009, 54: 17–25. 10.1016/j.archoralbio.2008.08.006PubMedCrossRef
101.
Zimmermann U, Woenckhaus C, Pietschmann S, Junker H, Maile S, Schultz K, Protzel C, Giebel J: Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome. Virchows Arch 2004, 445: 368–374. 10.1007/s00428-004-1103-4PubMedCrossRef
102.
Inokuchi J, Narula N, Yee DS, Skarecky DW, Lau A, Ornstein DK, Tyson DR: Annexin A2 positively contributes to the malignant phenotype and secretion of IL-6 in DU145 prostate cancer cells. Int J Cancer 2009, 124: 68–74. 10.1002/ijc.23928PubMedCrossRef
103.
Longerich T, Haller MT, Mogler C, Aulmann S, Lohmann V, Schirmacher P, Brand K: Annexin A2 as a differential diagnostic marker of hepatocellular tumors. Pathol Res Pract 2011, 207: 8–14. 10.1016/j.prp.2010.09.007PubMedCrossRef
104.
Takano S, Togawa A, Yoshitomi H, Shida T, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Tomonaga T: Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy. Ann Surg Oncol 2008, 15: 3157–3168. 10.1245/s10434-008-0061-5PubMedCrossRef
105.
Pena-Alonso E, Rodrigo JP, Parra IC, Pedrero JM, Meana MV, Nieto CS, Fresno MF, Morgan RO, Fernandez MP: Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma. Cancer Lett 2008, 263: 89–98. 10.1016/j.canlet.2007.12.029PubMedCrossRef
106.
Qi YJ, He QY, Ma YF, Du YW, Liu GC, Li YJ, Tsao GS, Ngai SM, Chiu JF: Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma. J Cell Biochem 2008, 104: 1625–1635. 10.1002/jcb.21727PubMedCrossRef
107.
Rodrigo JP, Lequerica-Fernandez P, Rosado P, Allonca E, Garcia-Pedrero JM, de Vicente JC: Clinical significance of annexin A2 downregulation in oral squamous cell carcinoma. Head Neck 2011, 33: 1708–1714. 10.1002/hed.21661PubMedCrossRef
108.
Zhang X, Zhi HY, Zhang J, Wang XQ, Zhou CN, Wu M, Sun YT, Liu ZH: Expression of annexin II in human esophageal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi 2003, 25: 353–355.PubMed
109.
Zhi H, Zhang J, Hu G, Lu J, Wang X, Zhou C, Wu M, Liu Z: The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma. Int J Cancer 2003, 106: 327–333. 10.1002/ijc.11225PubMedCrossRef
110.
Gillette JM, Chan DC, Nielsen-Preiss SM: Annexin 2 expression is reduced in human osteosarcoma metastases. J Cell Biochem 2004, 92: 820–832. 10.1002/jcb.20117PubMedCrossRef
111.
Chetcuti A, Margan SH, Russell P, Mann S, Millar DS, Clark SJ, Rogers J, Handelsman DJ, Dong Q: Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res 2001, 61: 6331–6334.PubMed
112.
Liu JW, Shen JJ, Tanzillo-Swarts A, Bhatia B, Maldonado CM, Person MD, Lau SS, Tang DG: Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 2003, 22: 1475–1485. 10.1038/sj.onc.1206196PubMedCrossRef
113.
Yee DS, Narula N, Ramzy I, Boker J, Ahlering TE, Skarecky DW, Ornstein DK: Reduced annexin II protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Arch Pathol Lab Med 2007, 131: 902–908.PubMed
114.
Sharma M, Blackman MR, Sharma MC: Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model. Exp Mol Pathol 2012, 92: 175–184. 10.1016/j.yexmp.2011.10.003PubMedCrossRef
115.
Sharma M, Ownbey RT, Sharma MC: Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol 2010, 88: 278–286. 10.1016/j.yexmp.2010.01.001PubMedCrossRef
116.
Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC: Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 2006, 81: 146–156. 10.1016/j.yexmp.2006.03.003PubMedCrossRef
117.
Sharma MR, Rothman V, Tuszynski GP, Sharma MC: Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action. Exp Mol Pathol 2006, 81: 136–145. 10.1016/j.yexmp.2006.03.002PubMedCrossRef
118.
Zhang F, Zhang L, Zhang B, Wei X, Yang Y, Qi RZ, Ying G, Zhang N, Niu R: Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells. J Proteome Res 2009, 8: 5041–5047. 10.1021/pr900461cPubMedCrossRef
119.
Shukla S, Govekar RB, Sirdeshmukh R, Sundaram CS, D'Cruz AK, Pathak KA, Kane SV, Zingde SM: Tumor antigens eliciting autoantibody response in cancer of gingivo-buccal complex. Proteomics Clin Appl 2007, 1: 1592–1604. 10.1002/prca.200700206PubMedCrossRef
120.
Shukla S, Pranay A, D'Cruz AK, Chaturvedi P, Kane SV, Zingde SM: Immunoproteomics reveals that cancer of the tongue and the gingivobuccal complex exhibit differential autoantibody response. Cancer Biomark 2009, 5: 127–135.PubMed
121.
Ohno Y, Izumi M, Kawamura T, Nishimura T, Mukai K, Tachibana M: Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br J Cancer 2009, 101: 287–294. 10.1038/sj.bjc.6605128PubMedCentralPubMedCrossRef
122.
Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, Hanash SM: An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA 2001, 98: 9824–9829. 10.1073/pnas.171320598PubMedCentralPubMedCrossRef
123.
Barua A, Edassery SL, Bitterman P, Abramowicz JS, Dirks AL, Bahr JM, Hales DB, Bradaric MJ, Luborsky JL: Prevalence of antitumor antibodies in laying hen model of human ovarian cancer. Int J Gynecol Cancer 2009, 19: 500–507. 10.1111/IGC.0b013e3181a39db1PubMedCentralPubMedCrossRef
124.
Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S: A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011, 253: 328–335. 10.1097/SLA.0b013e3181fd271cPubMedCentralPubMedCrossRef
125.
Heinzel S, Rea D, Offringa R, Pawelec G: The self peptide annexin II (208–223) presented by dendritic cells sensitizes autologous CD4+ T lymphocytes to recognize melanoma cells. Cancer Immunol Immunother 2001, 49: 671–678. 10.1007/s002620000163PubMedCrossRef
126.
Fukunaga Y, Bandoh S, Fujita J, Yang Y, Ueda Y, Hojo S, Dohmoto K, Tojo Y, Takahara J, Ishida T: Expression of cytokeratin 8 in lung cancer cell lines and measurement of serum cytokeratin 8 in lung cancer patients. Lung Cancer 2002, 38: 31–38.PubMedCrossRef
127.
Imai S, Nagano K, Yoshida Y, Okamura T, Yamashita T, Abe Y, Yoshikawa T, Yoshioka Y, Kamada H, Mukai Y: Development of an antibody proteomics system using a phage antibody library for efficient screening of biomarker proteins. Biomaterials 2011, 32: 162–169. 10.1016/j.biomaterials.2010.09.030PubMedCrossRef
128.
Kim TM, Jeong HJ, Seo MY, Kim SC, Cho G, Park CH, Kim TS, Park KH, Chung HC, Rha SY: Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray. Clin Cancer Res 2005, 11: 79–86.PubMed
129.
Wikman H, Kettunen E, Seppanen JK, Karjalainen A, Hollmen J, Anttila S, Knuutila S: Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 2002, 21: 5804–5813. 10.1038/sj.onc.1205726PubMedCrossRef
130.
Teramoto R, Minagawa H, Honda M, Miyazaki K, Tabuse Y, Kamijo K, Ueda T, Kaneko S: Protein expression profile characteristic to hepatocellular carcinoma revealed by 2D-DIGE with supervised learning. Biochim Biophys Acta 2008, 1784: 764–772. 10.1016/j.bbapap.2008.02.011PubMedCrossRef
131.
Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19: 264–271. 10.1038/modpathol.3800528PubMedCrossRef
132.
Hamrita B, Chahed K, Kabbage M, Guillier CL, Trimeche M, Chaieb A, Chouchane L: Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA). Clin Chim Acta 2008, 393: 95–102. 10.1016/j.cca.2008.03.017PubMedCrossRef
133.
Bonin S, Brunetti D, Benedetti E, Dotti I, Gorji N, Stanta G: Molecular characterisation of breast cancer patients at high and low recurrence risk. Virchows Arch 2008, 452: 241–250. 10.1007/s00428-007-0570-9PubMedCrossRef
134.
Obermajer N, Doljak B, Kos J: Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness. Mol Cancer 2009, 8: 88. 10.1186/1476-4598-8-88PubMedCentralPubMedCrossRef
135.
Liu F, Chen Z, Wang J, Shao X, Cui Z, Yang C, Zhu Z, Xiong D: Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. Neoplasia 2008, 10: 1275–1284.PubMedCentralPubMedCrossRef
136.
Liu F, Fan D, Qi J, Zhu H, Zhou Y, Yang C, Zhu Z, Xiong D: Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line. Life Sci 2008, 83: 496–501. 10.1016/j.lfs.2008.07.017PubMedCrossRef
137.
Ditzel HJ, Strik MC, Larsen MK, Willis AC, Waseem A, Kejling K, Jensenius JC: Cancer-associated cleavage of cytokeratin 8/18 heterotypic complexes exposes a neoepitope in human adenocarcinomas. J Biol Chem 2002, 277: 21712–21722. 10.1074/jbc.M202140200PubMedCrossRef
138.
Pfaff M, O'Connor R, Vollmers HP, Muller-Hermelink HK: Human monoclonal antibody against a tissue polypeptide antigen-related protein from a patient with a signet-ring cell carcinoma of the stomach. Cancer Res 1990, 50: 5192–5198.PubMed
139.
Gires O, Munz M, Schaffrik M, Kieu C, Rauch J, Ahlemann M, Eberle D, Mack B, Wollenberg B, Lang S: Profile identification of disease-associated humoral antigens using AMIDA, a novel proteomics-based technology. Cell Mol Life Sci 2004, 61: 1198–1207. 10.1007/s00018-004-4045-8PubMedCrossRef
140.
Le Naour F, Brichory F, Misek DE, Brechot C, Hanash SM, Beretta L: A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 2002, 1: 197–203. 10.1074/mcp.M100029-MCP200PubMedCrossRef
141.
Li L, Chen SH, Yu CH, Li YM, Wang SQ: Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray. J Proteome Res 2008, 7: 611–620. 10.1021/pr070525rPubMedCrossRef
142.
Gharib TG, Chen G, Wang H, Huang CC, Prescott MS, Shedden K, Misek DE, Thomas DG, Giordano TJ, Taylor JM: Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. Neoplasia 2002, 4: 440–448. 10.1038/sj.neo.7900257PubMedCentralPubMedCrossRef
143.
Yamashiro Y, Takei K, Umikawa M, Asato T, Oshiro M, Uechi Y, Ishikawa T, Taira K, Uezato H, Kariya K: Ectopic coexpression of keratin 8 and 18 promotes invasion of transformed keratinocytes and is induced in patients with cutaneous squamous cell carcinoma. Biochem Biophys Res Commun 2010, 399: 365–372. 10.1016/j.bbrc.2010.07.077PubMedCrossRef
144.
Kabukcuoglu S, Ozalp SS, Yalcin OT, Colak E, Abubakar AA: Comparison of histopathologic classification and surgical stage by cytokeratin 8 and cytokeratin 18 in endometrial cancer. Eur J Gynaecol Oncol 2010, 31: 641–644.PubMed
145.
Schaafsma HE, Van Der Velden LA, Manni JJ, Peters H, Link M, Rutter DJ, Ramaekers FC: Increased expression of cytokeratins 8, 18 and vimentin in the invasion front of mucosal squamous cell carcinoma. J Pathol 1993, 170: 77–86. 10.1002/path.1711700113PubMedCrossRef
146.
Warburg O, Wind F, Neglers E: The metabolism of tumors. London: Constable & Co.; 1930.
147.
Crowther M, Brown NJ, Bishop ET, Lewis CE: Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol 2001, 70: 478–490.PubMed
148.
Lukashev D, Ohta A, Sitkovsky M: Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues. Cancer Metastasis Rev 2007, 26: 273–279. 10.1007/s10555-007-9054-2PubMedCrossRef
149.
Semenza GL: Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001, 7: 345–350. 10.1016/S1471-4914(01)02090-1PubMedCrossRef
150.
151.
Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A: Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996, 271: 32529–32537. 10.1074/jbc.271.51.32529PubMedCrossRef
152.
Altenberg B, Greulich KO: Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004, 84: 1014–1020. 10.1016/j.ygeno.2004.08.010PubMedCrossRef
153.
Cao L, Li X, Zhang Y, Peng F, Yi H, Xu Y, Wang Q: Proteomic analysis of human ovarian cancer paclitaxel-resistant cell lines. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2010, 35: 286–294.PubMed
154.
Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, Castagnoli C, Migliorini P, Perconti G, Giallongo A, Milella M: An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer 2009, 125: 639–648. 10.1002/ijc.24355PubMedCrossRef
155.
Govekar RB, D'Cruz AK, Alok Pathak K, Agarwal J, Dinshaw KA, Chinoy RF, Gadewal N, Kannan S, Sirdeshmukh R, Sundaram CS: Proteomic profiling of cancer of the gingivo-buccal complex: Identification of new differentially expressed markers. Proteomics Clin Appl 2009, 3: 1451–1462.PubMed
156.
Hamaguchi T, Iizuka N, Tsunedomi R, Hamamoto Y, Miyamoto T, Iida M, Tokuhisa Y, Sakamoto K, Takashima M, Tamesa T, Oka M: Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. Int J Oncol 2008, 33: 725–731.PubMed
157.
Hennipman A, Smits J, van Oirschot B, van Houwelingen JC, Rijksen G, Neyt JP, Van Unnik JA, Staal GE: Glycolytic enzymes in breast cancer, benign breast disease and normal breast tissue. Tumour Biol 1987, 8: 251–263. 10.1159/000217529PubMedCrossRef
158.
Katayama M, Nakano H, Ishiuchi A, Wu W, Oshima R, Sakurai J, Nishikawa H, Yamaguchi S, Otsubo T: Protein pattern difference in the colon cancer cell lines examined by two-dimensional differential in-gel electrophoresis and mass spectrometry. Surg Today 2006, 36: 1085–1093. 10.1007/s00595-006-3301-yPubMedCrossRef
159.
Li C, Xiao Z, Chen Z, Zhang X, Li J, Wu X, Li X, Yi H, Li M, Zhu G, Liang S: Proteome analysis of human lung squamous carcinoma. Proteomics 2006, 6: 547–558. 10.1002/pmic.200500256PubMedCrossRef
160.
Lopez-Pedrera C, Villalba JM, Siendones E, Barbarroja N, Gomez-Diaz C, Rodriguez-Ariza A, Buendia P, Torres A, Velasco F: Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets. Proteomics 2006,6(Suppl 1):S293–299.PubMedCrossRef
161.
Mikuriya K, Kuramitsu Y, Ryozawa S, Fujimoto M, Mori S, Oka M, Hamano K, Okita K, Sakaida I, Nakamura K: Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol 2007, 30: 849–855.PubMed
162.
Qi Y, Chiu JF, Wang L, Kwong DL, He QY: Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics 2005, 5: 2960–2971. 10.1002/pmic.200401175PubMedCrossRef
163.
Shen J, Person MD, Zhu J, Abbruzzese JL, Li D: Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 2004, 64: 9018–9026. 10.1158/0008-5472.CAN-04-3262PubMedCrossRef
164.
Somiari RI, Sullivan A, Russell S, Somiari S, Hu H, Jordan R, George A, Katenhusen R, Buchowiecka A, Arciero C: High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics 2003, 3: 1863–1873. 10.1002/pmic.200300560PubMedCrossRef
165.
Takashima M, Kuramitsu Y, Yokoyama Y, Iizuka N, Fujimoto M, Nishisaka T, Okita K, Oka M, Nakamura K: Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics 2005, 5: 1686–1692. 10.1002/pmic.200401022PubMedCrossRef
166.
Tsai ST, Chien IH, Shen WH, Kuo YZ, Jin YT, Wong TY, Hsiao JR, Wang HP, Shih NY, Wu LW: ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur J Cancer 2010, 46: 1712–1723. 10.1016/j.ejca.2010.03.018PubMedCrossRef
167.
Tu SH, Chang CC, Chen CS, Tam KW, Wang YJ, Lee CH, Lin HW, Cheng TC, Huang CS, Chu JS: Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat 2010, 121: 539–553. 10.1007/s10549-009-0492-0PubMedCrossRef
168.
Wong CS, Wong VW, Chan CM, Ma BB, Hui EP, Wong MC, Lam MY, Au TC, Chan WH, Cheuk W, Chan AT: Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncol Rep 2008, 20: 89–98.PubMed
169.
Zhao J, Chang AC, Li C, Shedden KA, Thomas DG, Misek DE, Manoharan AP, Giordano TJ, Beer DG, Lubman DM: Comparative proteomics analysis of Barrett metaplasia and esophageal adenocarcinoma using two-dimensional liquid mass mapping. Mol Cell Proteomics 2007, 6: 987–999. 10.1074/mcp.M600175-MCP200PubMedCrossRef
170.
Zhou H, Chen CB, Lan J, Liu C, Liu XG, Jiang L, Wei F, Ma QJ, Dang GT, Liu ZJ: Differential proteomic profiling of chordomas and analysis of prognostic factors. J Surg Oncol 2010, 102: 720–727. 10.1002/jso.21674PubMedCrossRef
171.
Ito S, Honma T, Ishida K, Wada N, Sasaoka S, Hosoda M, Nohno T: Differential expression of the human alpha-enolase gene in oral epithelium and squamous cell carcinoma. Cancer Sci 2007, 98: 499–505. 10.1111/j.1349-7006.2007.00411.xPubMedCrossRef
172.
Chang GC, Liu KJ, Hsieh CL, Hu TS, Charoenfuprasert S, Liu HK, Luh KT, Hsu LH, Wu CW, Ting CC: Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res 2006, 12: 5746–5754. 10.1158/1078-0432.CCR-06-0324PubMedCrossRef
173.
Suzuki A, Iizuka A, Komiyama M, Takikawa M, Kume A, Tai S, Ohshita C, Kurusu A, Nakamura Y, Yamamoto A: Identification of melanoma antigens using a Serological Proteome Approach (SERPA). Cancer Genomics Proteomics 2010, 7: 17–23.PubMed
174.
Chang YS, Wu W, Walsh G, Hong WK, Mao L: Enolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clin Cancer Res 2003, 9: 3641–3644.PubMed
175.
Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L: Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 2012, 488: 337–342. 10.1038/nature11331PubMedCentralPubMedCrossRef
176.
Zhou W, Capello M, Fredolini C, Piemonti L, Liotta LA, Novelli F, Petricoin EF: Mass spectrometry analysis of the post-translational modifications of alpha-enolase from pancreatic ductal adenocarcinoma cells. J Proteome Res 2010, 9: 2929–2936. 10.1021/pr901109wPubMedCrossRef
177.
Hennipman A, van Oirschot BA, Smits J, Rijksen G, Staal GE: Glycolytic enzyme activities in breast cancer metastases. Tumour Biol 1988, 9: 241–248. 10.1159/000217568PubMedCrossRef
178.
Shih NY, Lai HL, Chang GC, Lin HC, Wu YC, Liu JM, Liu KJ, Tseng SW: Anti-alpha-enolase autoantibodies are down-regulated in advanced cancer patients. Jpn J Clin Oncol 2010, 40: 663–669. 10.1093/jjco/hyq028PubMedCrossRef
179.
Mojtahedi Z, Safaei A, Yousefi Z, Ghaderi A: Immunoproteomics of HER2-positive and HER2-negative breast cancer patients with positive lymph nodes. OMICS 2011, 15: 409–418. 10.1089/omi.2010.0131PubMedCrossRef
180.
Sato N, Nabeta Y, Kondo H, Sahara H, Hirohashi Y, Kashiwagi K, Kanaseki T, Sato Y, Rong S, Hirai I: Human CD8 and CD4 T cell epitopes of epithelial cancer antigens. Cancer Chemother Pharmacol 2000,46(Suppl):S86–90.PubMedCrossRef
181.
Zou L, Wu Y, Pei L, Zhong D, Gen M, Zhao T, Wu J, Ni B, Mou Z, Han J: Identification of leukemia-associated antigens in chronic myeloid leukemia by proteomic analysis. Leuk Res 2005, 29: 1387–1391. 10.1016/j.leukres.2005.04.021PubMedCrossRef
182.
Huang LJ, Chen SX, Luo WJ, Jiang HH, Zhang PF, Yi H: Proteomic analysis of secreted proteins of non-small cell lung cancer. Ai Zheng 2006, 25: 1361–1367.PubMed
183.
Dot C, Guigay J, Adamus G: Anti-alpha-enolase antibodies in cancer-associated retinopathy with small cell carcinoma of the lung. Am J Ophthalmol 2005, 139: 746–747. 10.1016/j.ajo.2004.10.044PubMedCrossRef
184.
He P, Naka T, Serada S, Fujimoto M, Tanaka T, Hashimoto S, Shima Y, Yamadori T, Suzuki H, Hirashima T: Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci 2007, 98: 1234–1240. 10.1111/j.1349-7006.2007.00509.xPubMedCrossRef
185.
Tomaino B, Cappello P, Capello M, Fredolini C, Sperduti I, Migliorini P, Salacone P, Novarino A, Giacobino A, Ciuffreda L: Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer. J Proteome Res 2011, 10: 105–112. 10.1021/pr100213bPubMedCrossRef
186.
Cappello P, Rolla S, Chiarle R, Principe M, Cavallo F, Perconti G, Feo S, Giovarelli M, Novelli F: Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer. Gastroenterology 2013.
187.
Rehman I, Azzouzi AR, Catto JW, Allen S, Cross SS, Feeley K, Meuth M, Hamdy FC: Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 2004, 64: 1238–1243. 10.1016/j.urology.2004.06.063PubMedCrossRef
188.
Forgber M, Trefzer U, Sterry W, Walden P: Proteome serological determination of tumor-associated antigens in melanoma. PLoS One 2009, 4: e5199. 10.1371/journal.pone.0005199PubMedCentralPubMedCrossRef
189.
Seweryn E, Pietkiewicz J, Bednarz-Misa IS, Ceremuga I, Saczko J, Kulbacka J, Gamian A: Localization of enolase in the subfractions of a breast cancer cell line. Z Naturforsch C 2009, 64: 754–758.PubMedCrossRef
190.
Mears R, Craven RA, Hanrahan S, Totty N, Upton C, Young SL, Patel P, Selby PJ, Banks RE: Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics 2004, 4: 4019–4031. 10.1002/pmic.200400876PubMedCrossRef
191.
Yu X, Harris SL, Levine AJ: The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res 2006, 66: 4795–4801. 10.1158/0008-5472.CAN-05-4579PubMedCrossRef
192.
Saldanha RG, Molloy MP, Bdeir K, Cines DB, Song X, Uitto PM, Weinreb PH, Violette SM, Baker MS: Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy. J Proteome Res 2007, 6: 1016–1028. 10.1021/pr060518nPubMedCrossRef
193.
Trojanowicz B, Winkler A, Hammje K, Chen Z, Sekulla C, Glanz D, Schmutzler C, Mentrup B, Hombach-Klonisch S, Klonisch T: Retinoic acid-mediated down-regulation of ENO1/MBP-1 gene products caused decreased invasiveness of the follicular thyroid carcinoma cell lines. J Mol Endocrinol 2009, 42: 249–260.PubMedCrossRef
194.
Dowling P, Meleady P, Dowd A, Henry M, Glynn S, Clynes M: Proteomic analysis of isolated membrane fractions from superinvasive cancer cells. Biochim Biophys Acta 2007, 1774: 93–101. 10.1016/j.bbapap.2006.09.014PubMedCrossRef
195.
Zitvogel L, Tesniere A, Kroemer G: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006, 6: 715–727. 10.1038/nri1936PubMedCrossRef
196.
Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA: High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997, 15: 3363–3367.PubMed
197.
Kondo H, Sahara H, Miyazaki A, Nabeta Y, Hirohashi Y, Kanaseki T, Yamaguchi A, Yamada N, Hirayama K, Suzuki M: Natural antigenic peptides from squamous cell carcinoma recognized by autologous HLA-DR8-restricted CD4+ T cells. Jpn J Cancer Res 2002, 93: 917–924. 10.1111/j.1349-7006.2002.tb01338.xPubMedCrossRef
Metadata
Title
Three are better than one: plasminogen receptors as cancer theranostic targets
Authors
Patrizia Ceruti
Moitza Principe
Michela Capello
Paola Cappello
Francesco Novelli
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Experimental Hematology & Oncology / Issue 1/2013
Electronic ISSN: 2162-3619
DOI
https://doi.org/10.1186/2162-3619-2-12

Other articles of this Issue 1/2013

Experimental Hematology & Oncology 1/2013 Go to the issue

Research

Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma

Research

A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC

Letter to the Editor

T-Cell/Histiocyte-Rich Large B-Cell Lymphoma of the Thyroid

Review

Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention

Research

The combined expression of the stromal markers fibronectin and SPARC improves the prediction of survival in diffuse large B-cell lymphoma

Review

The forgotten tale of immunoglobulin allotypes in cancer risk and treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits